SYGNIS is a German stocklisted company devoted to the development of novel, superior tools for molecular biology that play key roles in changing the way genomic and proteomic research is done today.
SYGNIS specializes in the development and commercialization of proprietary technologies and a commercial product portfolio addressing key challenges in molecular biology. With the acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, SYGNIS has added a complementary proteomic product portfolio. With this significant expansion SYGNIS portfolio now covers the entire workflow of molecular biology. Products are sold through a direct sales force and distribution partners in Europe, the US and Asia.
SYGNIS has offices in Germany, Spain and the UK, production sites in the UK and the US and sales offices in Asia.
The company is listed on the German Stock Exchange in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).
Company Details
- Employees
- 8
- Founded
- -
- Address
- ., Germany,spain,uk And Usa,spain
- Industry
- Biotechnology
- Website
- sygnis.com
- HQ
- Germany, Spain, UK and USA
Sygnis Questions
Sygnis's website is sygnis.com
Sygnis's LinkedIn profile is https://es.linkedin.com/company/sygnis
Sygnis has
8 employees.
View email and phone details for 8
employees at Sygnis.
Sygnis's industry is
Biotechnology
Sygnis's top competitors are
Dubai For The Export Of Poisonous Animals And Reptiles,
Cafe Scientifique Dubai,
4basebio,
Maxwell Innovation Lab Llc (Acquired By Dubai-Based Family Office),
Copal Scientific,
Genaptics,
Allinky Biopharma,
Biohope,
Landsteiner Genmed,
Dart: Design, Research & Technology.
Sygnis's categories are Biotechnology
Sygnis's founding year is 2012
